Neurogene (NGNE) Interest Coverage Ratio (2013 - 2026)
Neurogene (NGNE) reported Interest Coverage Ratio of 3705.44 for Q1 2026, up 71.41% on a YoY basis from 2161.77 in Q1 2025, and down 2670.89% quarter-over-quarter from 144.13 in Q4 2025.
Neurogene (NGNE) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Neurogene has reported Interest Coverage Ratio for 8 years, with the latest figure at 3705.44 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 71.41% year-over-year to 3705.44; the trailing twelve-month figure through Mar 2026 stood at 1678.14 (up 1109.74% YoY), and the FY2025 full-year result was 20665.6, down 200.21% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 3705.44, down from 144.13 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 144.13 in Q4 2025, with the low at 12959.5 in Q1 2025.
- Historically, Interest Coverage Ratio has averaged 4238.59 across 4 years, with a median of 3804.75 in 2023.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio tumbled 1141.11% — and 2025, when it jumped 101.34%.
- Neurogene's Interest Coverage Ratio stood at 866.65 in 2023, then plunged by 1141.11% to 10756.0 in 2024, then jumped by 101.34% to 144.13 in 2025, then tumbled by 2670.89% to 3705.44 in 2026.
- The last three Interest Coverage Ratio figures came in at 3705.44 (Q1 2026), 144.13 (Q4 2025), and 566.62 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | -3,705.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,705.44 |
| Dec 31, 2025 | 144.13 |
| Sep 30, 2025 | -566.62 |
| Jun 30, 2025 | -352.45 |
| Mar 31, 2025 | -12,959.50 |
| Dec 31, 2024 | -10,756.00 |
| Sep 30, 2024 | -7,393.33 |
| Jun 30, 2024 | -37.77 |
| Mar 31, 2024 | -6,259.67 |
| Dec 31, 2023 | -866.65 |
| Sep 30, 2023 | -3,804.75 |
| Jun 30, 2023 | -4,198.67 |
| Mar 31, 2023 | -4,345.00 |
| Mar 31, 2020 | -453.55 |
| Sep 30, 2015 | -1,257.75 |
| Jun 30, 2015 | -949.00 |
| Mar 31, 2015 | -1,067.67 |
| Dec 31, 2014 | 1,012.25 |
| Sep 30, 2014 | -3,141.00 |
| Jun 30, 2014 | -2,711.00 |